- Defendant in Lee Rigby machete murder trial: ‘I love al Qaeda’
- Obama lied about Syrian chemical attack, ‘cherry-picked’ intelligence: report
- MSNBC host: Obamacare a ‘wealthy white men’ racist word
- Democrat thwarts Nevada activist’s try to name peak after Reagan
- Congress ready to extend ban on plastic firearms
- Rogue reindeer runs from Santa, eludes police for hours
- Iran touts new laser that bolsters missile accuracy
- Satanists petition for statue at Oklahoma Statehouse
- Deadly N.Y. train derailment leads to Senate call for cameras at tracks
- WWII vet, 90, en route to Pearl Harbor event booted from flight
Latest Health_Medical_Pharma Items
Pfizer Inc. says it is halting a key study of its experimental blood thinner, apixaban, because of dangerous bleeding among patients with a history of heart disease.
Lawmakers have struck a deal to postpone a massive cut in Medicare pay for doctors, a senior congressional aide familiar with the details said Thursday.
Calling it the "forgotten epidemic," former Surgeon General C. Everett Koop urged Americans to end complacency about AIDS and put the deadly disease back on the radar screen.
An experimental drug boosted good cholesterol so high and dropped bad cholesterol so low in a study that doctors were stunned and voiced renewed hopes for an entirely new way of preventing heart attacks and strokes.
An experimental drug dramatically lowered bad cholesterol (LDL) while raising so-called good cholesterol (HDL) to record levels in a study of 1,623 people.
Medicare advisers on Wednesday supported the effectiveness of the prostate cancer drug Provenge, an innovative therapy that has prompted questions about the cost of medical care and the government's role in paying for it.
Four marketers of popular caffeinated, high-alcohol drinks have been sent warning letters that these products are not safe and cannot be portrayed as safe, federal officials said Wednesday.
VOTE OF CONFIDENCE: Medicare advisers said they are confident in the benefits of Provenge, an innovative prostate cancer drug that has generated controversy because of its $93,000 price tag. Medicare will make a final decision on whether to pay for the drug in March.
Women in their 40s with a moderately high family risk of breast cancer should get yearly mammograms, a new British study suggests.